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Effect of praziquantel treatment of Schistosoma
mansoni during pregnancy on immune responses
to schistosome antigens among the offspring:
results of a randomised, placebo-controlled trial
Robert Tweyongyere1,2*, Patrice A Mawa2, Macklyn Kihembo2, Frances M Jones3, Emily L Webb4, Stephen Cose2,4,
David W Dunne3, Birgitte J Vennervald5 and Alison M Elliott2,4
Abstract
Background: Offspring of women with schistosomiasis may exhibit immune responsiveness to schistosomes due
to in utero sensitisation or trans-placental transfer of antibodies. Praziquantel treatment during pregnancy boosts
maternal immune responses to schistosome antigens and reduces worm burden. Effects of praziquantel treatment
during pregnancy on responses among offspring are unknown.
Methods: In a trial of anthelminthic treatment during pregnancy in Uganda (ISRCTN32849447; http://www.
controlled-trials.com/ISRCTN32849447/elliott), offspring of women with Schistosoma mansoni were examined for
cytokine and antibody responses to schistosome worm (SWA) and egg (SEA) antigen, in cord blood and at age
one year. Relationships to maternal responses and pre-treatment infection intensities were examined, and
responses were compared between the offspring of women who did, or did not receive praziquantel treatment
during pregnancy.
Results: Of 388 S. mansoni-infected women studied, samples were obtained at age one year from 215 of their
infants. Stool examination for S. mansoni eggs was negative for all infants. Cord and infant samples were
characterised by very low cytokine production in response to schistosome antigens with the exception of cord
IL-10 responses, which were substantial. Cord and infant cytokine responses showed no association with maternal
responses. As expected, cord blood levels of immunoglobulin (Ig) G to SWA and SEA were high and correlated
with maternal antibodies. However, by age one year IgG levels had waned and were hardly detectable.
Praziquantel treatment during pregnancy showed no effect on cytokine responses or antibodies levels to SWA or
SEA either in cord blood or at age one year, except for IgG1 to SWA, which was elevated in infants of treated
mothers, reflecting maternal levels. There was some evidence that maternal infection intensity was positively
associated with cord blood IL-5 and IL-13 responses to SWA, and IL-5 responses to SEA, and that this association
was modified by treatment with praziquantel.
Conclusions: Despite strong effects on maternal infection intensity and maternal immune responses, praziquantel
treatment of infected women during pregnancy had no effect on anti-schistosome immune responses among
offspring by age one year. Whether the treatment will impact upon the offspring’s responses on exposure to
primary schistosome infection remains to be elucidated.
Trial registration: ISRCTN: ISRCTN32849447
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Background
Protection against infection encountered in the first few
weeks of childhood is thought to be mediated primarily
by maternally-derived immunoglobulin [1,2]. However, it
has been established that neonatal T cells are able to
respond to specific antigens [3-5], and neonatal B cells
are also capable of producing antibodies in response to
specific antigens [6]. Additionally, infection during preg-
nancy [6-8], or antigen exposure through immunisation
during pregnancy [9], may also lead to immunological
sensitisation of the developing foetus to that particular
infection or immunogen. For schistosome antigens, in
utero sensitisation has been shown to occur in up to 50%
of human neonates whose mothers had schistosomiasis
[6,10]. Possible mechanisms for such sensitisation include
direct exposure to antigens crossing the placenta [11-13]
or transfer of idiotypic antibodies that cross the placenta
[14,15]. Supporting the first hypothesis, Attallah and
colleagues [13] described the presence of a 63-KD
S. mansoni antigen in 86% of cord blood samples, sug-
gesting that a high proportion of infants in schistosomia-
sis endemic populations are exposed to worm antigens
in utero. Supporting the second hypothesis, studies in
mice have demonstrated that in utero idiotypic exposure
induces B and T cell responsiveness to schistosome anti-
gens recognised by the idiotype [16], and that this neona-
tal exposure may be an important immmunoregulatory
factor in subsequent schistosomiasis [17,18]. In addition,
studies have reported that the effects of helminth infec-
tion during pregnancy on immune responses in neonates
may also extend to non-helminth antigens [19,20].
It is estimated that approximately 40 million women of
child bearing age are infected with schistosomiasis [21],
and that the number of women with schistosomiasis
during pregnancy in Africa could be as high as 10 million
per year [22]. Previous policy has excluded pregnant and
lactating women from the control of schistosomiasis
using praziquantel treatment [23], but this policy was
rescinded following a review in 2002 [22,24]. Despite this,
there has been no information on the effects of prazi-
quantel treatment of schistosomiasis during pregnancy
on subsequent immune responses of the mothers’ babies.
We hypothesised that treatment of schistosomiasis dur-
ing pregnancy might impact upon in utero sensitisation
and thus the immune responsiveness of babies born to
infected and treated women. We previously showed that
praziquantel treatment during pregnancy boosted both
cytokine responses [25] and antibody levels [26] to schis-
tosome antigens in mothers six weeks after treatment.
We now report findings from a study of offspring of
women with S. mansoni infection during pregnancy. We
show that immune responsiveness of the offspring seen
in cord blood and in infants at age one year to schisto-
some antigens was lower than seen in their mothers. We
also show that praziquantel treatment induced boosts in
maternal immune responses to schistosome worm
(SWA) and egg (SEA) antigens were still evident at the
time of delivery, but there were no similar boost effects
seen among their offspring.
Methods
Study setting, subjects and sample collection
This study was nested within the larger ‘Entebbe Mother
and Baby Study’ (EMaBS), which was designed to investi-
gate the impact of helminths and their treatment on
the response to immunisation and on susceptibility to
infectious diseases in childhood in Uganda (ISRCTN
32849447). As previously described [27], EMaBS was con-
ducted within Entebbe municipality and the adjacent
Katabi sub-county in Uganda. The study was a randomised,
double-blind placebo-controlled trial of praziquantel versus
matching placebo and albendazole versus matching
placebo during pregnancy in a 2 × 2 factorial design.
Women were recruited to the study between April 2003
and November 2005. At enrolment, a stool sample was
obtained and examined for intestinal helminths including
S. mansoni infection. Two slides from a single stool sample
were examined by the Kato Katz method, as previously
described [26], and infection intensity categorised as unde-
tected, light (0-99 eggs per gram (epg)), moderate (100-399
epg) or heavy (> 400 epg). The randomised trial treatments
were given after obtaining the stool sample, and during the
second or third trimester of pregnancy. All women were
treated with both albendazole and praziquantel approxi-
mately six weeks after delivery.
For the current study, we focussed on women infected
with S. mansoni and their infants. Blood samples used in
this analysis were obtained from women within one week
following delivery, from cord blood, and from infants at
age one year. Cord blood samples were obtained, after
clamping, from the placental side of the cord using a nee-
dle and syringe. From November 2003, samples from
women with S. mansoni infection and their offspring were
examined for cytokine responses to schistosome worm
(SWA) and egg (SEA) antigens in a whole blood assay.
Stored plasma samples from S. mansoni-infected women
and their offspring were examined for levels of antibodies
to SWA and SEA antigens.
Possible contamination of cord blood with maternal
blood at time of birth was assessed by measuring beta-
human chorionic gonadotropin (bHCG) in cord blood
serum by ELISA (Diagnostic Automation Inc. California
USA). This hormone is found in high concentrations in
maternal blood, but does not cross the placenta [28].
Ethical consideration
Written informed consent was obtained from each parti-
cipant as previously described [27]. For the infants’
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participation, consent was obtained from the mother or
father or guardian if both parents were deceased. Ethical
approval was obtained from the Science and Ethics
Committee of Uganda Virus Research Institute - Minis-
try of Health, the Uganda National Council for Science
and Technology and the London School of Hygiene and
Tropical Medicine.
Whole blood culture and cytokine assay
Whole blood culture stimulation for cytokine responses
to SWA and SEA was performed as described elsewhere
[25,29,30]. Briefly, heparinised blood was diluted to a
final concentration of 1 in 4 with serum-free medium
(RPMI supplemented with glutamine, penicillin and
streptomycin) and 200 μl per well added to 96-well,
round-bottomed plates (TC Microwell, NUNC A/S, Ros-
kelde, Denmark). The blood was stimulated with SWA,
SEA or phytohaemagglutinin (PHA - Sigma, UK) at final
concentrations of 10 μg/ml, or was left unstimulated.
Cultures were incubated at 37°C with 5% CO2, and
supernatants harvested after 6 days. Supernatants were
virally inactivated with 0.03% tributyl phosphate and 1%
Tween 80 (Sigma) at room temperature for one hour and
stored at -80°C. Maternal and cord blood samples were
assessed for interferon gamma (IFNg), IL-2, IL-4, IL-5,
IL-13 and IL-10 responses whilst one year samples
were assessed for IFNg, IL-5, IL-13 and IL-10 responses.
SWA and SEA were prepared in Professor David Dunne’s
laboratory, as previously described [31]. Levels of endo-
toxin in the antigens, measured using a Limulus Amebo-
cyte Lysate Kit, QCL-1000 (BioWhittaker Inc, Walkersville,
MD, USA) were 0.086 EU/mg of SWA and 0.175 EU/mg
of SEA. At 10 μg/ml antigen concentration the endotoxin
levels in culture were therefore negligible (< 0.1 ng/ml) and
unlikely to cause any significant cytokine responses in
whole blood stimulation.
IFNg, IL-2, IL-4, IL-5 and IL-10 production in response
to SWA and SEA stimulation of blood was measured in
supernatants using OptEIA ELISA Kits (BD Pharmingen,
USA). For IL-13, antibody pairs (BD PharMingen, USA),
with standards from the National Institute for Biological
Standards and Controls (NIBSC, UK) were used. The
sensitivity of each assay, and cut-off for detectable
responses, was the lowest concentration on the standard
curve (7.8 pg/ml, except for IFNg which was 8.6 pg/ml
for maternal and cord responses and 26 pg/ml for age
one year responses). Cytokine concentration in unstimu-
lated wells was subtracted from concentrations in anti-
gen-stimulated wells to obtain the antigen-specific
response.
Assay of antibodies against schistosome antigens
Levels of IgE, IgG1, IgG2, IgG3 and IgG4 against SWA
and SEA were measured in plasma samples and in
duplicate by ELISA as previously described [26]. Briefly,
flat bottomed 96-well styrene microtitre-9205 plates
(Thermo Labsystems, USA) were coated with SWA (8 μg/
ml) or SEA (2.4 μg/ml) in 100 μl bicarbonate coating buf-
fer and incubated overnight at 4°C. A standard positive
pool was used for quantification of antibodies. Biotinylated
mouse anti-human monoclonal antibodies were used for
detection and were obtained from BD Pharmingen (San
Diego USA), with the exception of IgG3 which was
obtained from Zymed (S. San Francisco, USA). Poly-HRP-
streptavidin conjugate (Sanquin, Netherlands) was added
at a 1/4000 dilution. Plates were developed with OPD sub-
strate and the reaction stopped by addition of 25 μl per
well of 2 M sulphuric acid on observing the colour change
at 15 minutes for IgG1-4 and 20 minutes for IgE. Optical
densities (ODs) were recorded into data files using Delta-
SOFT II (BioMetalics, Inc USA) and exported into Micro-
soft Excel and Stata (StataCorp, USA). Concentrations
were calculated from ODs by interpolation from standard
curves using Stata 5.0. The sensitivity of the test was deter-
mined as the lowest standard concentration above which
levels were detectable (39 μg/ml, 0.7 μg/ml, 0.195 μg/ml,
0.32 μg/ml and 2.6 μg/ml for IgG1-4 and IgE to SWA
respectively; 2 μg/ml, 0.2 μg/ml, 0.022 μg/ml, 0.1 μg/ml
and 0.16 μg/ml for IgG1-4 and IgE to SEA respectively).
Statistical analysis
The analysis had five objectives. Firstly, we examined
whether the booster effects of treatment during pregnancy
on the maternal response that we have previously
observed were still apparent at time of delivery by compar-
ing cytokine responses and antibody levels between
women in the praziquantel and placebo groups. Secondly,
we examined the effect of praziquantel treatment during
pregnancy on the level of immune responsiveness of the
offspring to schistosome antigens. This was done by com-
paring the levels of cytokine production in response to
SWA and SEA in cord blood and at age one year between
offspring of women of the praziquantel and placebo
groups. Thirdly, we examined the effect of praziquantel
treatment on maternal antibody transfer by comparing
cord blood antibody levels between the praziquantel and
placebo groups. Fourthly, we examined for associations
between maternal immune responses and responses
in their offspring by correlation analysis of maternal anti-
bodies and cytokine responses with responses in cord
blood and at age one year. Lastly, we examined the effect
of maternal S. mansoni infection intensity on immune
responsiveness to schistosome antigens among the women
and their offspring by correlation analysis of infection
intensity with cytokine responses and antibody levels.
Cytokine and antibody responses to S. mansoni anti-
gens SWA and SEA showed skewed distributions, some
with large numbers of undetectable results, which were
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set to zero. Responses were transformed using log10(con-
centration + 1), but many distributions remained skewed.
For each cytokine and each antibody, the non-parametric
Wilcoxon ranksum test was used on the log-transformed
data to examine the effect of praziquantel treatment on
the level of response. Binary variables representing
detectable/non-detectable levels for each cytokine and
antibody were also analysed; logistic regression was used
to estimate odds ratios (ORs) and 95% CIs for the asso-
ciation between praziquantel treatment and having a
detectable response.
Spearman’s rank correlation coefficients were calcu-
lated to examine the relationship between maternal
responses and those in cord blood and at one year. The
relationship between S. mansoni infection intensity in the
mother and level of cytokine and antibody response in
cord blood, and at one year was also examined using
Spearman’s correlation. In order to examine whether the
effect of praziquantel treatment on immune responses
was modified by infection intensity, the Spearman’s cor-
relation coefficients for the relationship between infec-
tion intensity and cytokine response were compared
between the treatment arms by applying Fisher’s trans-
formation to the correlation coefficients and conducting
a z-test on these transformed values [32].
Results
Three hundred and eighty-eight women had S. mansoni
detected at enrolment and these constituted the nested
cohort within the larger EMaBs cohort for this study; 201
were randomized to placebo and 187 to praziquantel
treatment. Infection intensity at enrolment was pre-
viously reported [26]; 65% had light, 19% moderate and
16% heavy S. mansoni infection intensity. The median
egg count was 36 epg (range 12 to 7026 epg). At delivery
125 women in the placebo group and 127 women in the
praziquantel group provided blood samples. On average
the time between treatment and when the delivery sam-
ples were drawn was 100 days (SD 48 days).
Cord blood bHCG levels did not differ between the pla-
cebo and praziquantel group. Cord blood samples with
bHCG concentrations above 166 mIU/ml were consid-
ered as potentially contaminated with maternal blood
and were therefore excluded from the analysis; 14 cord
blood samples were excluded on this basis. Cord blood
obtained from 110 babies in the placebo group and 102
in the praziquantel group were included. At age one year,
225 infants, 107 from the placebo group and 118 from
the praziquantel group, provided blood and stool sam-
ples. None of these infants had eggs of S. mansoni
detected in their stool.
In the whole blood assays, cytokine levels in unstimu-
lated wells were generally low; medians (interquartile
ranges) for maternal IFNg, IL-2, IL-4, IL-5, IL-10 and IL-
13 levels were 39.5(16.0, 67.0), 16 (0, 30.2), 0 (0, 15.0),
0 (0,11.0) 20.5 (8, 32.0) and 0 (0,9.3) pg/ml respectively.
Cord blood levels were 0(0, 19.9), 0 (0, 13.8), 0(0,0),
0 (0,0), 8(0, 27.1) and 0(0, 0) pg/ml respectively. Levels
among infants were 0(0,59.5), 0 (0, 0), 13.0 (0, 34.0),
0 (0,10.3) for IFNg, IL-5, IL-10 and IL13 respectively. The
levels did not differ between the placebo and praziquantel
groups at any time point. Only results for net production
in response to stimulation are shown hereafter.
Maternal cytokine and antibody responses to SWA and
SEA at delivery
Whole blood assay and antibody measurement were per-
formed on maternal samples drawn from women within
a week after delivery. Measurement of cytokine responses
was performed on 164 maternal blood samples of which
75 (45.7%) were from women who received placebo dur-
ing pregnancy while 89 (54.3%) were from women who
received praziquantel. Specific antibody levels were mea-
sured in 252 samples drawn from women within a week
after delivery; of these, 125 (49.6%) received placebo and
127 (50.4%) received praziquantel.
At delivery, maternal cytokine responses to SWA sti-
mulation (Figure 1A) were significantly higher for all
cytokines tested in mothers that were treated compared
to those that were not (p = 0.002 for IFNg, IL-4 & IL-10;
p < 0.001 for IL-2, IL-5 &IL-13). Similarly, in response to
SEA stimulation (Figure 1B), production of IL-4, IL-5
and IL-13, but not IFNg or IL-10, was significantly higher
in the praziquantel treated group compared to placebo
(p = 0.022 for IL-4 and < 0.001 for IL-5 & IL-13).
Maternal antibodies at delivery showed higher levels of
SWA-specific IgE (p = 0.054), and IgG1 (p < 0.001) in
treated mothers (Figure 1C). For SEA-specific antibodies
(Figure 1D), IgE levels were higher in the treated
mothers than in the placebo group (p = 0.048) while
IgG4 levels were lower in treated mothers compared to
the placebo group (p = 0.001).
Overall, these results show that praziquantel treatment
in the second or third trimester induces an extended
and significant boost, still detectable at delivery, in
schistosome antigen-specific maternal cytokine
responses, and in most antibody levels.
Cord blood and infant cytokine responses to S. mansoni
antigens
Whole blood assay and measurement of cytokine
responses was performed on 144 samples of cord blood
and 225 blood samples from infants at age one year. Of
the 144 cord blood samples, 70 (48.6%) were from babies
of women who received placebo during pregnancy and
74 (51.4%) were from babies of women who received pra-
ziquantel. Of the 225 samples taken at age one year, 107
(47.6%) were from babies whose mothers received
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placebo and 118 (52.4%) from babies of mothers who
received praziquantel.
Cord blood cytokine responses to both SWA and SEA
were generally low, the exception being noticeable
amounts of IL-10 produced in response to both SWA
and SEA antigens (Figures 2A and 2B, respectively).
Cord blood production of IFNg, IL-2, IL-4, IL-5, IL-13
and IL-10 in response to SWA stimulation was seen in
29.4%, 28.5%, 13.9%, 12.5%, 15.5% and 58.2% of the
samples respectively, and the corresponding figures for
responses to SEA were 32.2%, 32.9%, 13.9%, 13.9%,
18.3%, and 58.2% respectively. Overall 81.4% and 80.0%
of the samples produced at least one of the cytokines in
response to SWA and SEA respectively. On excluding
IL-10 (in order to focus on cytokines more likely to be
of lymphocyte origin), 55.3% and 62.4% of the cord sam-
ples produced at least one of the cytokines in response
to SWA and SEA respectively.
The levels of cytokine responses to SWA and SEA in
cord were mostly lower than in mothers at delivery
(compare Figures 1A and 1B with Figures 2A and 2B;
also additional file 1) and, for each cytokine, there was
no significant association between the maternal and
cord blood cytokine response. Comparing maternal
treatment arms, praziquantel during pregnancy had no
significant effect on any specific cytokine response in
cord blood. That is, the differences between the placebo
and praziquantel groups seen among maternal responses
were not seen among the cord responses (Figure 2A and
2B). Thus, overall, praziquantel treatment during preg-
nancy appeared to have no effect on the cytokine
response in cord blood.
However, there was a suggestion that the association
between maternal infection intensity and cord blood
responses differed depending on whether the mother
received praziquantel or placebo. Cord blood IL-5 and
IL-13 responses to SWA, and IL-5 responses to SEA,
were positively correlated with maternal infection inten-
sity at enrolment in the placebo group but not in the
praziquantel group; IL-2 responses showed a similar
trend (Table 1) although a formal test of differences
between each pair of correlation coefficients found no
Figure 1 Cytokine responses and antibody levels among women at delivery who received praziquantel treatment during pregnancy
(PZQ) or who were left untreated (placebo). A and B show levels of cytokine production to SWA and SEA respectively plotted as log10
(cytokine concetration (pg/ml)+1). C and D show antibody levels to SWA and SEA respectively plotted as log10 (antibody concentration (in μg/
mL)+1). Corresponding data on cytokine and antibody levels are given in additional file 1 and additional file 2 respectively. *p < 0.05; **p <
0.001.
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Figure 2 Cytokine responses to SWA and SEA in cord blood (A and B) and infants at age one year (C and D). Box plots show levels of cytokine
production plotted by maternal praziquantel treatment; that is, women who received praziquantel treatment during pregnancy (PZQ) or who were
left untreated (placebo). Plotted on the y-axis is log10 (cytokine concentration (pg/mL) + 1). Corresponding data are given in additional file 1.
Table 1 Spearman correlation between cord blood responses and maternal infection intensity at enrolment during
pregnancy
Cytokine responses to SWA Cytokine responses to SEA
Spearman
coefficients
p-value p-value for
difference between
correlations
Spearman
coefficients
p-value p-value for difference
between correlations
IFNg Placebo (n = 70) 0.0426 0.726 0.45 0.1326 0.274 0.26
Praziquantel (n = 73) -0.0901 0.449 -0.0634 0.594
IL-2 Placebo (n = 65) 0.2134 0.088 0.28 0.1468 0.243 0.21
Praziquantel (n = 72) 0.0214 0.858 -0.0789 0.510
IL-4 Placebo (n = 66) -0.1362 0.275 0.64 0.0064 0.960 0.98
Praziquantel (n = 71) -0.2166 0.070 0.0111 0.927
IL-5 Placebo (n = 70) 0.2744 0.021 0.09 0.2271 0.059 0.40
Praziquantel (n = 74) -0.0169 0.886 0.0830 0.482
IL-
13
Placebo (n = 69) 0.2644 0.028 0.09 0.1554 0.202 0.39
Praziquantel (n = 73) -0.0331 0.781 0.0044 0.971
IL-
10
Placebo (n = 69) 0.0178 0.885 0.77 -0.0384 0.754 0.92
Praziquantel (n = 72) 0.0691 0.564 -0.0572 0.633
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strong evidence for a difference. Further exploration of
the data seemed to suggest that the lack of association
within the praziquantel group was explained by a ten-
dency for praziquantel to induce increased cord blood
responses among infants of mothers with low intensity
infection and decreased responses among infants of
mothers with moderate to heavy infection (Table 2).
Responses in infants at one year still showed low levels
of cytokine production in response to both SWA and SEA
(Figure 2C and 2D, respectively). There was no difference
in the responses in infants at one year between those that
were born of mothers who were treated with praziquantel,
and those that were not. For each cytokine, infants’
responses were not associated with cord responses.
Anti-schistosome antibody levels in cord blood and
infants at age one year
Antibody levels were measured in 212 cord blood sam-
ples and 127 blood samples from infants at age one
year. Of the 212 cord blood samples, 110 (51.9%) were
from the placebo group and 102 (48.1%) from the prazi-
quantel group. Of the 127 infant samples 62 (48.8%)
were offspring of mothers who received placebo and 65
(51.2%) were offspring of mothers who received
praziquantel.
Overall, the pattern of IgG isotypes to schistosome
antigens in cord blood was similar to that seen in
mothers at delivery, regardless of their treatment group:
high levels of IgG1 and low levels of IgG2 and IgG3 to
SWA (compare Figure 1C with Figure 3A); high levels
of IgG1 and low levels of IgG2, IgG3 and IgG4 to SEA
(compare Figure 1D with Figure 3B). On the other
hand, IgE to SWA and SEA was detectable in very few
cord blood samples (2/212 and 34/212 respectively).
As expected [33], cord blood levels of IgG to SWA and
SEA were correlated with maternal levels in both treat-
ment groups with Spearman’s coefficients ranging from
0.66-0.91, (p < 0.001) for all IgG isotypes (Figure 4),
although there were some subtle differences, in keeping
with recognised differences in transport across the pla-
centa [34]. For example, in both the placebo and prazi-
quantel groups, maternal levels of IgG3 to SWA were
higher than cord blood levels and maternal levels of IgG1
to SEA were lower than cord blood levels (additional file
2). Paralleling maternal responses, treatment with prazi-
quantel was associated with increased cord blood
Table 2 Cytokine responses (geometric mean concentration (pg/mL) +1) and antibody levels (geometric mean
concentration (μg/mL) +1) of cord blood by infection intensity and by treatment
For women with light
infectiona
For women with moderate to
heavy infectionb
For women with light
infectiona
For women with moderate to
heavy infectionb
Cord blood cytokine responses to SWA Cord blood cytokine responses to SEA
IFNg placebo 2.28 (1.47, 3.53) 2.36 (1.19, 4.69) 2.57 (1.65, 3.99) 3.39 (1.65, 6.97)
praziquantel 3.18 (1.90, 5.34) 1.45 (1.01, 2.09) 1.84 (1.30, 2.60) 1.95 (1.08, 3.52)
IL-2 placebo 2.02 (1.40, 2.91) 3.07 (1.35, 6.96) 2.36 (1.57, 3.55) 4.65 (2.12, 10.2)
praziquantel 1.97 (1.31, 2.95) 2.44 (1.23, 4.83) 2.39 (1.47, 3.89) 1.67 (1.05, 2.64)
IL-4 placebo 1.39 (0.97, 1.98) 1.12 (0.89, 1.41) 1.29 (0.96, 1.73) 1.35 (0.87, 2.08)
praziquantel 1.79 (1.23, 2.60) 1.12 (0.94, 1.34) 1.53 (1.13, 2.08) 1.26 (0.90, 1.76)
IL-5 placebo 1.06 (0.97, 1.15) 1.73 (1.08, 2.77) 1.09 (1.00, 1.20) 1.57 (1.02, 2.40)
praziquantel 1.53 (1.09, 2.14) 1.36 (0.95, 1.96) 1.30 (1.02, 1.67) 1.46 (0.99, 2.16)
IL-
13
placebo 1.22 (0.99, 1.51) 1.68 (1.04, 2.72) 1.76 (1.24, 2.50) 1.60 (1.06, 2.40)
praziquantel 1.49 (1.08, 2.05) 1.52 (0.84, 2.76) 1,40 (1.04, 1.87) 1.63 (0.92, 2.87)
IL-
10
placebo 10.09 (5.38, 18.92) 6.72 (2.66, 17.04) 11.64 (5.95, 22.77) 10.32 (3.83, 27.8)
praziquantel 5.91 (3.18, 10.99) 7.40 (3.18, 17.23) 7.08 (3.69, 13.58) 5.96 (2.39, 14.87)
Cord antibodies against SWA Cord antibodies against SEA
IgG1 placebo 39.87 (25.24, 62.99) 166.41 (104.02, 266.23) 53.94 (38.99, 74.63) 36.20 (21.16, 61.91)
praziquantel 73.70 (44.18, 122.94) 317.85 (243.33, 415.19) 46.22 (31.35, 68.15) 29.22 (17.16, 49.77)
IgG2 placebo 2.14 (1.72, 2.68) 4.48 (3.03, 6.62) 8.33 (6.70, 10.35) 7.12 (5.38, 9.43)
praziquantel 2.63 (2.04, 3.38) 5.80 (4.29, 7.84) 7.72 (5.99, 9.95) 6.49 (4.95, 8.52)
IgG3 placebo 1.79 (1.61, 2.00) 1.64 (1.45, 1.86) 1.28 (1.21, 1.36) 1.17 (1.10, 1.25)
praziquantel 1.59 (1.46, 1.73) 2.10 (1.77, 2.49) 1.24 (1.18, 1.31) 1.36 (1.23, 1.51)
IgG4 placebo 1.11 (0.96, 1.28) 2.24 (1.27, 3.97) 4.07 (3.24, 5.11) 7.32 (5.04, 10.6)
praziquantel 1.27 (1.01, 1.60) 2.96 (1.55, 5.65) 3.42 (2.71, 4.32) 7.61 (5.71, 10.16)
a for cytokines n = 45-48 in placebo group and 49-51 in praziquantel group; for antibodies n = 73 placebo group and n = 67 in praziquantel group
b for cytokine responses n = 20 - 22 in placebo group and 23 in praziquantel group; for antibodies n = 37 in placebo group and n = 35 in praziquantel group
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antibody levels to SWA; this was statistically significant
for IgG1 (also see Figure 3A).
Levels of maternal and cord blood IgG1, IgG2 and
IgG4 against SWA and IgG4 against SEA were positively
correlated with maternal enrolment S. mansoni infection
intensity while levels of IgG1, IgG2 and IgG3 against
SEA showed a trend of negative correlation with mater-
nal S. mansoni infection intensity (Table 3). Findings in
cord blood mirrored those in maternal blood.
Among the infants at age one year, there were hardly
any detectable antibodies against SWA (Figure 3C);
IgG1, IgG2 and IgG3 were detectable in 1/127, 6/127
and 19/127 infants respectively. No infant had detectable
levels of IgG4 and IgE to SWA. In contrast to what was
seen for antibodies to SWA, several infants had detect-
able IgG and IgE to SEA (Figure 3D); IgG1, IgG2 IgG3
and IgE to SEA were detectable in 42/127, 5/127, 18/
127 and 89/127 infants respectively. These antibodies
among infants were not associated with maternal or
cord blood antibodies. Praziquantel treatment during
pregnancy showed no significant effects on antibodies to
SEA among infants.
Discussion
This study describes the effect of S. mansoni infection
and of praziquantel treatment during pregnancy on
immune responsiveness to schistosome adult worm
(SWA) and egg (SEA) antigens in the offspring of the
affected women, examined in cord blood and in infants
at age one year.
Our results show that the praziquantel-induced boost
in worm-specific immune responses that was previously
observed at six weeks after treatment [25,26] lasts at least
up to the time of delivery. However, there was no evi-
dence of a direct correlation between maternal and cord,
or maternal and infant immune responses to schistosome
antigens, except for the expected relationships between
maternal and cord blood antibody levels.
In the current study IFNg, IL-2, IL-4, IL-5, and IL-13
production in response to SWA or SEA stimulation was
seen (for each cytokine) in approximately 10 to 30% of
cord blood samples. Several earlier studies have also
shown that uninfected children of infected mothers can
have immune responses specific to S. mansoni [35-37] or
S. haematobium [10]. Although these studies differed
Figure 3 Antibodies against SWA and SEA in cord blood (A and B) and infants at age one year (C and D). Box plots show levels of each
antibody by maternal treatment; that is, women who received praziquantel treatment during pregnancy (PZQ) or who were left untreated
(placebo). Plotted on the y-axis is log10 (antibody concentration (μg/mL) + 1). Corresponding data are given in additional file 2. *p = 0.0004.
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from ours in the in vitro assaying protocols used (using
peripheral blood mononuclear cells rather than whole
blood, or proliferation rather than cytokine assays), the
findings nevertheless corroborate each other and suggest
that a significant proportion of infants of infected women
acquire T cell sensitisation in utero. Apart from IL-10,
the levels of response observed in cord blood were much
lower than those that were found among the mothers
Figure 4 Correlations between maternal and cord blood levels of antibody to SWA and SEA. *Spearman’s correlation coefficients;
p < 0.001.
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during pregnancy [25], or reported in infected children
and adults living in schistosomiasis endemic areas
[38-40]. Low T-cell responses in cord blood are expected
since immune cells in cord blood are functionally imma-
ture [41-44].
However, an important finding was that the observed
level and frequency of IL-10 response to schistosome
antigens in cord blood was higher than that for other
measured cytokine responses, and dominated the cord
blood response profile. High IL-10 production is in line
with the generally down-regulated responses of cord
blood cells, although non-IL-10-mediated suppression
may also be important in the fetal and neonatal response
to antigens [45,46]. Because we were measuring whole
blood culture supernatants, we have no information on
the cellular sources of this IL-10. Possible sources include
cells participating in the innate response, as well as T and
B cells. One particular possibility may be fetal lineage
regulatory T cells, which have been demonstrated to as
biased towards immune tolerance [47,48]. If antigen-spe-
cific memory T or B cells are involved, this IL-10 produc-
tion may reflect the acquisition of tolerance to
schistosome antigens resulting from exposure in utero,
with long-term implications for the response of such
children on exposure to infection. The mechanisms of
this effect deserve further investigation.
Given the measured effects of praziquantel during
pregnancy on the prevalence and intensity of infection
among mothers in this cohort (reduced by 81.9% [26]),
and therefore, presumably, on levels of schistosome anti-
gen in the maternal circulation, as well as the measured
effects on maternal antibody and cytokine responses, we
were surprised to observe no overall effect of praziquan-
tel during pregnancy on in utero sensitisation, as assessed
by cord blood responses to schistosome antigens. Several
potential mechanisms may relate to this. One possible
explanation is that sensitisation occurred prior to the
provision of the intervention - equally in both groups. A
second possible explanation is that the fetal and neonatal
immune system itself has a default pathway towards
tolerance [48] and thus the induction of measured anti-
gen-specific responses (other than IL-10) was minimised
- again equally in both groups. Alternatively, the possible
interactions between maternal infection intensity and
praziquantel may be important. Our data suggests a weak
increase in sensitisation to worm antigens with increasing
maternal infection intensity, especially for IL-5 and IL-13,
which occurred in the placebo group, but not in the
praziquantel group (although, the formal test for effect
modification between the two groups was not signifi-
cant). A plausible mechanism by which praziquantel
might so modify an effect of maternal infection intensity
may be as follows. Among infants of mothers with light
infections, praziquantel may increase sensitisation by
causing the release of antigen from dying worms into the
maternal circulation and/or by boosting levels of anti-
schistosome antibodies crossing the placenta. On the
other hand, among infants of mothers with moderate to
heavy infections, praziquantel treatment might reduce
sensitisation by reducing the duration of fetal exposure to
schistosome antigens. These suggestions are speculative
and must be considered with caution given the weak evi-
dence for these effects. Overall, our results do not support
the hypothesis that praziquantel treatment during preg-
nancy influences sensitisation of the fetus to schistosome
antigens.
Levels of IgG antibodies against SWA and SEA in cord
blood were high and their correlation with maternal antibo-
dies was expected since IgG antibodies cross the placenta
[33]. Cord blood IgG1 to SWA, in particular, was increased
as a result of maternal treatment with praziquantel. Antibo-
dies acquired by trans-placental transfer are known to pro-
vide the major protection against bacterial and viral
infections in early life [49]. Some protection against schisto-
some infection has been attributed to high levels of worm-
specfic IgE [50,51], which was conspicuously absent in cord
Table 3 Association between maternal or cord blood antibody levels and maternal infection intensity at enrolment
Maternal Antibodies to
SWA
Maternal Antibodies to
SEA
Cord blood antibodies to
SWA
Cord blood antibodies to
SEA
IgG1 Placebo 0.45 (< 0.001) -0.09 (0.314) 0.51 (< 0.001) -0.15 (0.105)
Praziquantel 0.53 (< 0.001) -0.06 (0.517) 0.53 (< 0.001) -0.18 (0.062)
IgG2 Placebo 0.22 (0.013) -0.21 (0.019) 0.32 (< 0.001) -0.20 (0.039)
Praziquantel 0.39 (< 0.001) -0.15 (0.099 0.45 (< 0.001) -0.13 (0.192)
IgG3 Placebo -0.10 (0.244) -0.24 (0.008) -0.10 (0.31) -0.33 (< 0.001)
Praziquantel 0.43 (< 0.001) 0.06 (0.532) 0.33 (< 0.001) 0.04 (0.674)
IgG4 Placebo 0.24 (0.008) 0.40 (< 0.001) 0.23 (0.016) 0.35 (< 0.001)
0.31 (0.0003) 0.38 (< 0.001) 0.23 (0.019) 0.44 (< 0.001)
IgE Placebo 0.29 (0.0009) -0.17 (0.062) 0.02 (0.798)
Praziquantel 0.21 (0.017) -0.02 (0.855) -0.03 (0.732)
Shown are Spearman’s correlation coefficients (p-values); For maternal antibodies N = 125 in placebo group and 127 in praziquantel group. For cord blood
antibodies N = 110 in placebo group and 102 in the praziquantel group.
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blood, however, maternal antibodies against schistosome
antigens might modify the offspring’s response to infection.
In our setting, any such effect may not have been observed,
as any infection that might have occurred during the first
year of life was below detectable levels and antibody of
maternal origin had waned by age one year. None of the
infants in our study were found to be excreting S. mansoni
eggs at detection sensitivity based on examination of a sin-
gle stool sample. However, the low cytokine responses and
low levels of IgE and IgG1 to SEA observed in several
infants may actually be indicative of some low level early-
stage infection not detected by single stool examinations. If
so, this would corroborate a recent epidemiological study
[52] that showed antibodies to SEA detectable in preschool
children and infants as young as nine months old. Although
the level of cytokine response to schistosome antigens in
one-year olds was very low and no relationship between
cord and infant responses was found, it will be important
to determine whether or not in utero sensitisation does
influence the subsequent response to schistosome antigens
when children in the cohort do became detectably infected.
Conclusions
This study found that although praziquantel treatment
during pregnancy caused a boost in maternal immune
responses to schistosome antigens that persisted up to
the time of delivery, it had no overall influence on the
immune responsiveness of uninfected offspring to schis-
tosome antigens at age one year. There was a suggestion
of an interaction between maternal infection intensity
and the effect of praziquantel on in utero sensitisation
to schistosome antigens. It will be of interest to deter-
mine whether praziquantel treatment during pregnancy
impacts on the infant response when primary infection
is encountered. This remains a question to be explored.
Additional material
Additional file 1: Levels of cytokine response to schistosome worm
antigen (SWA) and schistosome egg antigen (SEA) in maternal blood
at delivery, cord blood and infant blood at age one year, by
praziquantel versus placebo treatment during pregnancy. A PDF file
of a table showing levels of cytokine production following stimulation of
either maternal cord or infant blood with SWA or SEA. Shown are median
cytokine concentrations in pg/mL in whole blood culture supernatants.
Additional file 2: Levels of antibodies to schistosome worm antigen
(SWA) and schistosome egg antigen (SEA) in maternal blood at
delivery, cord blood and infant blood at age one year, by
praziquantel versus placebo treatment during pregnancy. A PDF file
of a table showing the median plasma concentrations in μg/mL of
antibodies to SWA and SEA and P-values for the ranksum comparison
between maternal and cord blood levels.
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